{"id":109865,"date":"2024-03-15T17:30:37","date_gmt":"2024-03-15T15:30:37","guid":{"rendered":"https:\/\/ivi-fertility.com\/?p=109865"},"modified":"2024-03-14T17:46:30","modified_gmt":"2024-03-14T15:46:30","slug":"recurrent-miscarriages","status":"publish","type":"post","link":"https:\/\/ivi-fertility.com\/blog\/recurrent-miscarriages\/","title":{"rendered":"Metformin improves reproductive outcomes in patients with insulin resistance"},"content":{"rendered":"

Every year, the scientific community in reproductive medicine gathers at the Annual Meeting of the Society for Reproductive Investigation (SRI).<\/a> This year’s edition took place in the city of Vancouver, Canada. Researchers from around the world shared the latest advances in research<\/strong> focused on enhancing reproductive environments and providing hope to women and couples in need of reproductive medicine to fulfill their desire to start a family.<\/p>\n

What is the influence of insulin resistance in recurrent miscarriages?<\/strong><\/h2>\n

Among the most prominent studies by IVI researchers is “Metformin treatment decreases clinical miscarriage and improves live birth rates in infertile patients with insulin resistance.” This work demonstrates how metformin treatment reduces clinical miscarriage rates and improves live birth rates in women undergoing assisted reproduction processes with insulin resistance<\/strong>. It is worth noting that metformin is an oral antidiabetic drug<\/strong> of the biguanide type. It helps control blood glucose levels, decrease glucose absorption from food, and reduce glucose production in the liver.<\/p>\n

Imbalance in insulin resistance during embryo implantation and pregnancy leads to elevated levels of maternal and fetal blood glucose. This results in complications that may lead to miscarriage. The use of metformin has been described as a treatment that leads to a decrease in blood glucose levels<\/strong> without associated risks. In addition it improves endometrial function, positioning it as a possible treatment for women where insulin resistance is a significant factor potentially related to poorer reproductive outcomes. In this regard, we evaluated the effect of metformin on the reproductive outcomes of these women<\/em>,” explains Dr. Hortensia Ferrero, researcher at the IVI Foundation and author of this study.<\/p>\n

Recurrent miscarriages affect approximately 2-5% of reproductive-aged patients<\/strong>. Various pathologies have been described as possible causes of pregnancy loss:<\/p>\n